Article

Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: What's on the Horizon for CAR T-Cell Therapies

Author(s):

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, June 2, 2020 at 8 PM EST.

Date/Time: Tuesday, June 2, 2020 at 8 PM EST

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells. We will feature a panel of leading experts to discuss important topics and considerations surrounding CAR T-cell therapies and the patient populations impacted during this time.

Click here to register today!

Course Topics:

  • Highlights from ASCO CAR T-cell abstracts and presentations
  • Updates on CAR T-cell clinical trials
  • New and novel CAR T-cell therapies

Associate Professor Section Chief, Indolent Lymphoma Section Chief, New Drug Development Department Lymphoma/Myeloma UT MD Anderson Cancer Center

Matthew Lunning, DO, Associate Professor, Internal Medicine Medical Director, Lymphoma Research Division of Oncology & Hematology University of Nebraska Medical Center

Ahmed Galal, MD, FRACP, MSc,Professor of Medicine Division of Hematologic Malignancies and Cellular Therapy Duke University School of Medicine

Sponsored By:

Related Videos
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Tom van Meerten, MD, PhD, hematologist, Department of Hematology, University Medical Center Groningen
Andrew Ip, MD
Minoo Battiwalla, MD, MS
David C. Fisher, MD
Amitkumar Mehta, MD
Jasmin M. Zain, MD
Marco Davila, MD, PhD
Sattva S. Neelapu, MD